Alprostadil (Caverject/MUSE) and Rosuvastatin Interaction

Why This Combination Comes Up in Clinical Practice

Men prescribed alprostadil for erectile dysfunction (ED) frequently take statins for dyslipidemia or cardiovascular risk reduction. Rosuvastatin is the most-prescribed statin in the United States, with over 30 million dispensed prescriptions annually according to ClinCalc drug usage statistics. ED prevalence rises in parallel with cardiovascular disease burden. The Massachusetts Male Aging Study reported that complete ED affected 9.6% of men aged 40 to 70, with vascular risk factors doubling the likelihood [1]. Because these two conditions overlap so frequently, clinicians and patients need clear guidance on whether the combination poses any pharmacologic risk.

The short answer: it does not. Alprostadil and rosuvastatin occupy different metabolic compartments, act through unrelated receptor systems, and have been co-prescribed for decades without signal generation in post-marketing surveillance databases [2].

Pharmacokinetic Analysis: No Metabolic Overlap

Alprostadil (prostaglandin E1) is a naturally occurring eicosanoid administered either by intracavernosal injection (Caverject) or intraurethral pellet (MUSE). After injection, approximately 80% of circulating alprostadil is metabolized in a single pass through the pulmonary vascular bed via beta-oxidation and omega-oxidation of the fatty-acid side chain [3]. The cytochrome P450 system plays no measurable role in alprostadil clearance. Plasma half-life is under 1 minute. The drug does not undergo hepatic first-pass metabolism in any clinically relevant quantity.

Rosuvastatin follows an entirely separate clearance route. Unlike atorvastatin or simvastatin, rosuvastatin undergoes minimal CYP-mediated metabolism. The FDA-approved prescribing information for Crestor states that CYP2C9 is responsible for limited metabolism, producing the N-desmethyl metabolite, which has roughly one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent compound [4]. Approximately 90% of rosuvastatin's elimination occurs through biliary excretion of unchanged drug. Rosuvastatin is a substrate of organic anion-transporting polypeptide 1B1 (OATP1B1), OATP1B3, and breast cancer resistance protein (BCRP).

Alprostadil does not inhibit or induce OATP1B1, OATP1B3, BCRP, CYP2C9, or any other transporter or enzyme relevant to rosuvastatin disposition. The converse is also true. No in-vitro or clinical pharmacokinetic study has identified a bidirectional interaction between these two agents [5].

Pharmacodynamic Considerations: Additive Vasodilation

The one area that warrants clinical attention is pharmacodynamic. Alprostadil is a direct vasodilator. It relaxes smooth muscle in the corpus cavernosum through cyclic AMP (cAMP)-mediated pathways, but systemically absorbed drug also dilates peripheral vasculature. Blood pressure reductions of 5 to 10 mmHg systolic have been documented after intracavernosal injection at therapeutic doses of 10 to 20 mcg [6].

Rosuvastatin produces modest blood-pressure-lowering effects independent of its lipid activity. A meta-analysis published in the American Journal of Hypertension found that statins reduced systolic blood pressure by a mean of 1.9 mmHg (95% CI: 0.7 to 3.1) in hypertensive patients [7]. The mechanism likely involves improved endothelial nitric oxide bioavailability.

Combined, these effects could produce transient drops in blood pressure. For most patients, this is inconsequential. For patients already on antihypertensives (particularly alpha-blockers or nitrates), the additive vasodilation deserves documentation in the clinical note and a brief counseling conversation. Alprostadil's FDA label explicitly warns against concomitant use with other vasoactive intracavernosal agents, but statins are not included in that warning category [8].

Severity Rating Across DDI Databases

Drug interaction databases classify this pair consistently. A low-severity or no-interaction rating applies.

Lexicomp: No interaction listed between alprostadil and rosuvastatin.

Micromedex: No monograph exists for this specific drug pair, indicating no identified interaction of clinical significance.

Clinical Pharmacology (Elsevier): No interaction flagged.

The absence of a monograph is itself informative. Major DDI databases maintain records only for pairs where at least a theoretical mechanism or case report exists. The alprostadil-rosuvastatin pair lacks both. This absence aligns with the pharmacokinetic reality described above: two drugs metabolized in entirely different organ systems (lung vs. liver/biliary) through non-overlapping enzymatic and transporter pathways [9].

By contrast, drugs that do interact meaningfully with rosuvastatin include gemfibrozil (which inhibits OATP1B1, raising rosuvastatin AUC by 1.9-fold), cyclosporine (7.1-fold AUC increase), and certain protease inhibitors [4]. Alprostadil shares none of these inhibitory properties.

Monitoring Recommendations for Co-Prescribed Patients

No special laboratory monitoring is required beyond standard care for each drug individually.

For rosuvastatin, the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol recommends a fasting lipid panel 4 to 12 weeks after initiation and every 3 to 12 months thereafter [10]. Baseline hepatic transaminases should be checked before starting therapy. Creatine kinase (CK) testing is indicated only when patients report new-onset muscle symptoms.

For alprostadil, the Caverject prescribing information recommends in-office dose titration starting at 2.5 mcg, with blood pressure monitoring during the titration visit [8]. Once a maintenance dose is established, routine office visits every 3 to 6 months suffice. Penile examination should be performed periodically to assess for fibrotic changes, which occur in approximately 7.8% of patients using intracavernosal alprostadil over 18 months [11].

The only additive monitoring consideration: if a patient reports dizziness or lightheadedness after alprostadil injection while on rosuvastatin (especially if also on antihypertensives), a seated and standing blood-pressure check should be performed at the next visit.

Dose Adjustments: None Required

Neither drug requires dose modification when the other is added or discontinued. This stands in contrast to genuine statin interactions. For example, the rosuvastatin label caps the dose at 5 mg daily when co-administered with cyclosporine [4]. No comparable restriction applies to concomitant alprostadil use.

The typical rosuvastatin dosing range remains 5 to 40 mg daily based on LDL-C target and cardiovascular risk category. Alprostadil intracavernosal doses range from 2.5 to 40 mcg per injection (maximum 60 mcg), with the majority of responders achieving adequate erections at 10 to 20 mcg [8]. MUSE intraurethral doses range from 125 to 1 to 000 mcg.

Statin Myopathy and Alprostadil: No Additive Risk

A concern patients sometimes raise is whether alprostadil could worsen statin-related muscle symptoms. It does not. Statin-associated muscle symptoms (SAMS) arise from mitochondrial dysfunction in skeletal muscle, impaired coenzyme Q10 synthesis, and possible disruption of sarcolemmal cholesterol content [12]. These mechanisms have no intersection with prostaglandin E1 signaling.

The STOMP trial (N=420) established that statins increase CK levels by a small but statistically significant amount even in asymptomatic patients and that myalgia occurred in 9.4% of statin-treated vs. 4.6% of placebo-treated subjects [13]. Alprostadil does not alter CK kinetics, does not impair mitochondrial electron transport, and does not affect mevalonate pathway intermediates. Patients experiencing SAMS should discuss the muscle symptoms with their prescriber, but alprostadil is not a contributing factor.

Cardiovascular Benefits of the Combination: Aligned Pharmacology

There is a biologically coherent argument that the two drugs complement each other. Rosuvastatin improves endothelial function through LDL-C reduction and pleiotropic anti-inflammatory effects. The JUPITER trial (N=17,802) demonstrated a 44% reduction in major cardiovascular events with rosuvastatin 20 mg vs. placebo in patients with elevated hsCRP [14]. Endothelial health directly influences erectile function. The penile artery (1 to 2 mm diameter) is often the earliest vascular bed to manifest atherosclerotic changes.

Alprostadil bypasses the endothelium entirely by directly activating EP2 and EP4 receptors on cavernosal smooth muscle, raising intracellular cAMP regardless of endothelial NO production [3]. In patients whose endothelial dysfunction is severe enough to render PDE5 inhibitors ineffective, alprostadil remains effective because its mechanism does not depend on intact endothelial signaling.

The two drugs therefore address different nodes of the same vascular pathophysiology. Rosuvastatin works upstream to slow atherosclerotic progression. Alprostadil works downstream to produce erections despite existing vascular damage. A 2014 observational cohort published in the Journal of Sexual Medicine found that statin users who required intracavernosal alprostadil had lower rates of dose escalation over 24 months compared to non-statin users, suggesting preserved vascular responsiveness [15].

Patient Counseling Points

When a patient asks whether Caverject or MUSE is safe with their rosuvastatin, the answer is direct: yes. Here are the specific counseling points to cover.

Timing: No special timing separation is needed. Rosuvastatin can be taken at any time of day, and alprostadil is used on-demand before sexual activity. The two do not need to be staggered.

Blood pressure awareness: Patients should sit or lie down for 5 to 10 minutes after intracavernosal injection, especially during the first few uses. This is standard alprostadil counseling regardless of statin use, but worth reinforcing.

Muscle symptoms: If a patient develops new muscle pain, weakness, or dark urine, they should contact their clinician promptly. This is a statin-class concern unrelated to alprostadil. Stopping alprostadil will not resolve statin myopathy.

Alcohol: Both drugs interact with alcohol independently. Alcohol potentiates alprostadil-induced hypotension and impairs hepatic statin metabolism at heavy-consumption levels. Patients should limit alcohol around the time of alprostadil use [8].

Priapism: The risk of prolonged erection (priapism) with alprostadil is approximately 1% per injection [16]. Rosuvastatin does not increase this risk. Patients should seek emergency care for any erection lasting longer than 4 hours.

When a Real Interaction Does Exist: Alprostadil Drug Pairs That Require Caution

While the rosuvastatin combination is safe, other drug pairs involving alprostadil do require vigilance.

Anticoagulants (warfarin, heparin): Intracavernosal injection carries a bleeding risk. Patients on anticoagulants may develop penile hematomas. The Caverject label recommends caution in anticoagulated patients [8].

Antihypertensives: Alpha-blockers (tamsulosin, doxazosin) combined with alprostadil may produce symptomatic hypotension. Blood pressure should be checked during the initial titration visit.

Other vasoactive intracavernosal agents: Papaverine and phentolamine are sometimes combined with alprostadil in compounded "trimix" formulations. These combinations require careful dose titration and should only be prepared by specialty pharmacies under physician supervision.

PDE5 inhibitors: Concurrent use of sildenafil, tadalafil, or vardenafil with alprostadil is not recommended by the FDA due to the risk of prolonged erection and severe hypotension [8]. Some urologists do use them sequentially (not simultaneously) in refractory cases, but this is an off-label approach requiring informed consent.

Rosuvastatin appears in none of these caution categories.